Iatrogenic hyperadrenocorticism in 28 dogs

Abstract

Twenty-eight dogs with iatrogenic hyperadrenocorticism were studied. The most common clinical signs were cutaneous lesions (27/28), polydipsia (21/28), polyuria (19/28), and lethargy (16/28). The most predominant findings on biochemical profile were elevated alkaline phosphatase (ALP, 15/28) and alanine transferase (ALT, 14/28); hypercholesterolemia (14/28); elevated aspartate transferase (AST, 12/28); and elevated triglycerides (12/18). Baseline cortisol levels of all 28 dogs were at the lower end of the reference range and exhibited suppressed or no response to adrenocorticotropic hormone (ACTH) stimulation. The mean time for each dog to show initial improvement of clinical signs after corticosteroid withdrawal was six weeks, with another mean time of 12 weeks to demonstrate complete remission.

Glucocorticoid Therapy

“…Other constituents of the "stress leukogram" were also found, but to a lesser extent (Huang et al, 1999). In dogs with iatrogenic hyperadrenocorticism, eosinopenia was seen in 18 out of 28 dogs and was the most frequent finding.…”

“…Clinical signs and laboratory abnormalities of iatrogenic hyperadrenocorticism are identical to those of the endogenous form of the disease. Resolution may not always be complete; for instance, persistence of calcinosis cutis and of pulmonary mineralization has been reported, and there may be color change in new hair growth (Huang et al, 1999;Blois et al, 2009). These signs may even occur within hours after the first dose.…”

Long‐term follow‐up in dogs with idiopathic eosinophilic bronchopneumopathy treated with inhaled steroid therapy

“…3 µg/dL); this value was taken because it was the highest post‐ACTH cortisol concentration reported within the case series of Huang et al . ().…”

Endocrine and Immunologic Effects of Inhaled Fluticasone Propionate in Healthy Dogs

“…GC are relatively contraindicated in dogs with active concurrent infections (including respiratory infections), predisposing factors for infection, certain types of heart disease, and diabetes mellitus, and in those receiving concurrent treatment with nonsteroidal anti‐inflammatory drugs 3 . Additionally, GC treatment can result in suppression of the hypothalamic–pituitary–adrenal axis (HPAA) 4–7 …”